|
1
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors - definition, clinical, histological,
immunohistochemical, and molecular genetic features and
differential diagnosis. Virchows Arch. 438:1–12. 2001.
|
|
2
|
Hirota S, Isozaki K, Moriyama Y, et al:
Gain-of-function mutations of c-kit in human gastrointestinal
stromal tumors. Science. 279:577–580. 1998.
|
|
3
|
Heinrich MC, Corless CL, Duensing A, et
al: PDGFRA activating mutations in gastrointestinal stromal tumors.
Science. 299:708–710. 2003.
|
|
4
|
Dematteo RP, Heinrich MC, El-Rifai WM and
Demetri G: Clinical management of gastrointestinal stromal tumors:
before and after STI-571. Hum Pathol. 33:466–477. 2002.
|
|
5
|
Edmonson JH, Marks RS, Buckner JC and
Mahoney MR: Contrast of response to dacarbazine, mitomycin,
doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with
advanced malignant gastrointestinal stromal tumors and patients
with other advanced leiomyosarcomas. Cancer Invest. 20:605–612.
2002.
|
|
6
|
Demetri GD, von Mehren M, Blanke CD, et
al: Efficacy and safety of imatinib mesylate in advanced
gastrointestinal stromal tumors. N Engl J Med. 347:472–480.
2002.
|
|
7
|
DeMatteo RP, Lewis JJ, Leung D, et al: Two
hundred gastrointestinal stromal tumors: recurrence patterns and
prognostic factors for survival. Ann Surg. 231:51–58. 2000.
|
|
8
|
Antonescu CR, Besmer P, Guo T, et al:
Acquired resistance to imatinib in gastrointestinal stromal tumor
occurs through secondary gene mutation. Clin Cancer Res.
11:4182–4190. 2005.
|
|
9
|
Mendel DB, Laird AD, Xin X, et al: In
vivo antitumor activity of SU11248, a novel tyrosine kinase
inhibitor targeting vascular endothelial growth factor and
platelet-derived growth factor receptors: determination of a
pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res.
9:327–337. 2003.
|
|
10
|
Demetri GD, van Oosterom AT, Garrett CR,
et al: Efficacy and safety of sunitinib in patients with advanced
gastrointestinal stromal tumor after failure of imatinib: a
randomised controlled trial. Lancet. 368:1329–1338. 2006.
|
|
11
|
Demetri GD, Huang X, Garrett CR, et al:
Novel statistical analysis of long-term survival to account for
crossover in a phase III trial of sunitinib (SU) vs. placebo (PL)
in advanced GIST after imatinib (IM) failure. J Clin Oncol.
26:105242008.
|
|
12
|
George S, Blay JY, Casali PG, et al:
Clinical evaluation of continuous daily dosing of sunitinib malate
in patients with advanced gastrointestinal stromal tumour after
imatinib failure. Eur J Cancer. 45:1959–1968. 2009.
|
|
13
|
Reichardt P, Kang Y, Ruka W, et al:
Detailed analysis of survival and safety with sunitinib (SU) in a
worldwide treatment-use trial of patients with advanced GIST. J
Clin Oncol. 26(Suppl 15): 105482008.
|
|
14
|
Houk BE, Bello CL, Poland B, et al:
Relationship between exposure to sunitinib and efficacy and
tolerability endpoints in patients with cancer: results of a
pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother
Pharmacol. 66:357–371. 2010.
|
|
15
|
Saponara M, Pantaleo MA, Nannini M and
Biasco G: Chronic therapy in gastrointestinal stromal tumors
(GISTs): the big gap between theory and practice. Target Oncol.
7:243–246. 2012.
|
|
16
|
Joensuu H, Trent JC and Reichardt P:
Practical management of tyrosine kinase inhibitor-associated side
effects in GIST. Cancer Treat Rev. 37:75–88. 2011.
|
|
17
|
Najjar YG, Elson P, Wood LS, et al:
Association of a 2-weeks-on and 1-week-off schedule of sunitinib
with decreased toxicity in metastatic renal cell carcinoma. J Clin
Oncol. 31(Suppl 6): 4062013.
|
|
18
|
Atkinson BJ, Kalra S, Wang X, Tannir NM
and Jonasch E: A single-center retrospective review of outcomes
associated with sunitinib alternative schedule compared to
traditional schedule. J Clin Oncol. 31(Suppl 6): 3812013.
|
|
19
|
Britten CD, Kabbinavar F, Hecht JR, et al:
A phase I and pharmacokinetic study of sunitinib administered daily
for 2 weeks, followed by a 1-week off period. Cancer Chemother
Pharmacol. 61:515–524. 2008.
|
|
20
|
Reichardt P, Kang YK, Rutkowski P, et al:
Continued sunitinib treatment after progressive disease (PD) in a
worldwide treatment-use trial of patients (pts) with
gastrointestinal stromal tumor (GIST). In: Poster presented at the
37th ESMO congress; Vienna, Austria. September 28–October 2, 2012;
(abstr 1490P).
|
|
21
|
Demetri GD, Reichardt P, Kang YK, et al:
GRID study investigators: Efficacy and safety of regorafenib for
advanced gastrointestinal stromal tumours after failure of imatinib
and sunitinib (GRID): an international, multicentre, randomised,
placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013.
|
|
22
|
National Cancer Institute. National Cancer
Institute common terminology criteria for adverse events version
4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
Accessed June 14, 2010
|
|
23
|
Maleddu A, Pantaleo MA, Nannini M, et al:
Mechanisms of secondary resistance to tyrosine kinase inhibitors in
gastrointestinal stromal tumours (Review). Oncol Rep. 21:1359–1366.
2009.
|
|
24
|
Italiano A, Cioffi A, Coco P, et al:
Patterns of care, prognosis, and survival in patients with
metastatic gastrointestinal stromal tumors (GIST) refractory to
first-line imatinib and second-line sunitinib. Ann Surg Oncol.
19:1551–1559. 2012.
|
|
25
|
Kinirons MT and O’Mahony MS: Drug
metabolism and ageing. Br J Clin Pharmacol. 57:540–544. 2004.
|
|
26
|
Antoun S, Baracos VE, Birdsell L, Escudier
B and Sawyer MB: Low body mass index and sarcopenia associated with
dose-limiting toxicity of sorafenib in patients with renal cell
carcinoma. Ann Oncol. 21:1594–1598. 2010.
|
|
27
|
Telli ML, Witteles RM, Fisher GA and
Srinivas S: Cardiotoxicity associated with the cancer therapeutic
agent sunitinib malate. Ann Oncol. 19:1613–1618. 2008.
|
|
28
|
Rini BI, Cohen DP, Lu DR, et al:
Hypertension as a biomarker of efficacy in patients with metastatic
renal cell carcinoma treated with sunitinib. J Natl Cancer Inst.
103:763–773. 2011.
|
|
29
|
George S, Reichardt P, Lechner T, et al:
Hypertension as a potential biomarker of efficacy in patients with
gastrointestinal stromal tumor treated with sunitinib. Ann Oncol.
23:3180–3187. 2012.
|
|
30
|
Schmidinger M, Vogl UM, Bojic M, et al:
Hypothyroidism in patients with renal cell carcinoma: blessing or
curse? Cancer. 117:534–544. 2011.
|
|
31
|
Puzanov I, Michaelson MD, Cohen DP, et al:
Evaluation of hand-foot syndrome (HFS) as a potential biomarker of
sunitinib (SU) efficacy in patients (pts) with metastatic renal
cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST). J
Clin Oncol. 29(Suppl): 211132011.
|
|
32
|
Eskens FA and Verweij J: The clinical
toxicity profile of vascular endothelial growth factor (VEGF) and
vascular endothelial growth factor receptor (VEGFR) targeting
angiogenesis inhibitors; a review. Eur J Cancer. 42:3127–3139.
2006.
|
|
33
|
DeMatteo RP, Maki RG, Singer S, et al:
Results of tyrosine kinase inhibitor therapy followed by surgical
resection for metastatic gastrointestinal stromal tumor. Ann Surg.
245:347–352. 2007.
|
|
34
|
Gronchi A, Fiore M, Miselli F, et al:
Surgery of residual disease following molecular-targeted therapy
with imatinib mesylate in advanced/metastatic GIST. Ann Surg.
245:341–346. 2007.
|
|
35
|
Pantaleo MA, Di Battista M, Catena F, et
al: Surgical debulking of gastrointestinal stromal tumors: is it a
reasonable option after second-line treatment with sunitinib? J
Cancer Res Clin Oncol. 134:625–630. 2008.
|
|
36
|
Hakimé A, Le Cesne A, Deschamps F, et al:
A role for adjuvant RFA in managing hepatic metastases from
gastrointestinal stromal tumors (GIST) after treatment with
targeted systemic therapy using kinase inhibitors. Cardiovasc
Intervent Radiol. 37:132–139. 2014.
|
